Diabetes Research and Clinical Practice
Volume 74 , Pages S119-S122 , December 2006

Aspart and lispro insulin, is there any difference when used with an insulin pump treatment?

  • Paolo Di Bartolo

      Affiliations

    • Diabetes Unit, Department of Digestive and Metabolic Diseases, Local Health Unit of Ravenna, Ravenna, Italy
    • Corresponding Author InformationCorresponding author. Address for correspondence: Paolo Di Bartolo, MD, U.O di Diabetologia, Dipartimento di Malattie Digestive e Metaboliche, AUSL Provincia di Ravenna, CMP, Via Fiume Montone Abbandonato 134, I-48100 Ravenna, Italy. Tel.: +39 05 4428 6326; Fax: +39 05 4428 6327
    • ,
  • Francesca Pellicano

      Affiliations

    • Diabetes Unit, Department of Digestive and Metabolic Diseases, Local Health Unit of Ravenna, Ravenna, Italy
    • ,
  • Antonio Scaramuzza

      Affiliations

    • Diabetes Unit, Department of Digestive and Metabolic Diseases, Local Health Unit of Ravenna, Ravenna, Italy
    • ,
  • Tiziano Fabbri

      Affiliations

    • Diabetes Unit, Department of Digestive and Metabolic Diseases, Local Health Unit of Ravenna, Ravenna, Italy
    • ,
  • Piero Melandri

      Affiliations

    • Diabetes Unit, Department of Digestive and Metabolic Diseases, Local Health Unit of Ravenna, Ravenna, Italy
    • ,
  • Valerio Miselli

      Affiliations

    • Diabetes Unit, Scandiano Hospital, Local Health Unit of Reggio Emilia, Reggio Emilia, Italy
    • ,
  • T. Casetti

      Affiliations

    • Diabetes Unit, Department of Digestive and Metabolic Diseases, Local Health Unit of Ravenna, Ravenna, Italy
    • ,
  • Francesco Cannatà

      Affiliations

    • Diabetes Unit, Department of Digestive and Metabolic Diseases, Local Health Unit of Ravenna, Ravenna, Italy

References 

  1. Nathan DM , Cleary PA , Backlund JY , Genuth SM , Lachin JM , Orchard TJ , et al.   Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes . N Engl J. Med . 2005;22:2643–2653
  2. Muggeo M , Zoppini G , Bonora E , Brun E , Bonadonna RC , Moghetti P , et al.   Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: The Verona Diabetes Study . Diabetes Care . 2000;23:45–50
  3. Home P . Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes . Curr Med Res Opin . 2005;21:989–998
  4. von Mach MA , Brinkmann C , Hansen T , Weilemann LS , Beyer J . Differences of pharmacokinetic and pharmacodynamic of insulin lispro and aspart in healthy volunteers . Exp. Clin Endocrinol Diabetes . 2002;110:416–419
  5. Hedman CA , Lindstrom T , Arnqvist HJ . Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in Type 1 diabetes . Diabetes Care . 2001;24:1120–1121
  6. Homko C , Deluzio A , Jimenez C , Kolaczynski JW , Boden G . Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects . Diabetes Care . 2003;26:2027–2031
  7. Plank J , Wutte A , Brunner G , Siebenhofer A , Semlitsch B , Sommer R , et al.   A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes . Diabetes Care . 2002;25:2053–2057
  8. Hirsch LB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, et al. Insulin Aspart CSII/MDI Comparison Study Group. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII . Diabetes Care . 2005;2:533–538
  9. Colquitt J , Royle P , Waugh N . Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis . Diabet Med . 2003;20:863–866
  10. Bode B , Weinstein R , Bell D , McGill J , Nadeau D , Raskin P , et al.   Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes . Diabetes Care . 2002;25:439–444
  11. Becker DI . Pediatric use of insulin pumps: longer infusion site lifetime with NovoLog . Diabetes Care . 2002;25:1663
  12. Poulsen C , Langkjaer L , Worsoe C . Precipitation of insulin products used for continuous subcutaneous insulin infusion . Diabetes Technol Ther . 2005;7:142–150

PII: S0168-8227(06)70013-4

doi: 10.1016/S0168-8227(06)70013-4

Diabetes Research and Clinical Practice
Volume 74 , Pages S119-S122 , December 2006

Article Tools